Clinical Trial Update: A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia [Phase 1]

View source ↗

Summary

The Phase 1 trial of TER-1754 for hereditary hemorrhagic telangiectasia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• TER-1754 (TER-1754)

Snippet

Sponsor: Terremoto Biosciences Inc. | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Status: WITHDRAWN